Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DaShenLin Pharmaceutical Group CoSHSE:603233 +2.43%93 5-Year Yield-on-Cost % is 8.31 as of Aug. 28, 2026, which is 184% above its 10-year median of 2.93. GuruFocus rates SHSE:603233 with a GF Score™ of 93/100 and a GF Value™ of ¥18.30 (Fairly Valued). The stock has 4 warning signs investors should review. Among 277 Healthcare Providers & Services companies, DaShenLin Pharmaceutical Group Co ranks better than 88.09% on this metric.
The historical rank and industry rank for DaShenLin Pharmaceutical Group Co's 5-Year Yield-on-Cost % or its related term are showing as below:
SHSE:603233'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.93 Med: 2.93 Max: 9.09
Current: 8.31
During the past 13 years, DaShenLin Pharmaceutical Group Co's highest Yield on Cost was 9.09. The lowest was 0.93. And the median was 2.93.
SHSE:603233's 5-Year Yield-on-Cost % is ranked better than 88.09% of 277
companies
in the Healthcare Providers & Services industry
Industry Median: 3.03
vs SHSE:603233: 8.31
DaShenLin Pharmaceutical Group Co (SHSE:603233) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
DaShenLin Pharmaceutical Group Co 5-Year Yield-on-Cost % Related Terms
DaShenLin Pharmaceutical Group Co 5-Year Yield-on-Cost % Competitor Comparison
For the Pharmaceutical Retailers subindustry, DaShenLin Pharmaceutical Group Co's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DaShenLin Pharmaceutical Group Co 5-Year Yield-on-Cost % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, DaShenLin Pharmaceutical Group Co's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where DaShenLin Pharmaceutical Group Co's 5-Year Yield-on-Cost % falls into.
DaShenLin Pharmaceutical Group Co 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
DaShenLin Pharmaceutical Group Co (SHSE:603233) has a 5-Year Yield-on-Cost % of 8.31 as of Aug. 28, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on DaShenLin Pharmaceutical Group Co and its competitors. This is 184% above median its historical median of 2.93. Over the past decade, DaShenLin Pharmaceutical Group Co's 5-Year Yield-on-Cost % has ranged from 0.93 to 9.09. According to the industry distribution chart, DaShenLin Pharmaceutical Group Co ranks #33 out of 277 companies in the Healthcare Providers & Services industry, placing it in the top 11.9%.
Is DaShenLin Pharmaceutical Group Co's 5-Year Yield-on-Cost % too high?
DaShenLin Pharmaceutical Group Co's current 5-Year Yield-on-Cost % of 8.31 is 184% above median its 10-year median of 2.93. Over the past 10 years, this metric has ranged from a low of 0.93 to a high of 9.09. The Healthcare Providers & Services industry median 5-Year Yield-on-Cost % is 3.03. DaShenLin Pharmaceutical Group Co's value of 8.31 is 174.3% above this industry median. Based on the distribution chart, DaShenLin Pharmaceutical Group Co ranks #33 out of 277 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, DaShenLin Pharmaceutical Group Co has a GF Score™ of 93/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does DaShenLin Pharmaceutical Group Co's 5-Year Yield-on-Cost % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, DaShenLin Pharmaceutical Group Co ranks #33 out of 277 companies for 5-Year Yield-on-Cost %. This places DaShenLin Pharmaceutical Group Co in the top 12% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 3.03. DaShenLin Pharmaceutical Group Co's value of 8.31 is 174.3% above this benchmark. Historically, DaShenLin Pharmaceutical Group Co's own 5-Year Yield-on-Cost % has ranged from 0.93 to 9.09 over the past decade. While the company's 10-year median is 2.93 vs. the industry median of 3.03, DaShenLin Pharmaceutical Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Healthcare Providers & Services company?
The median 5-Year Yield-on-Cost % among Healthcare Providers & Services companies is 3.03, based on 277 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DaShenLin Pharmaceutical Group Co's current 5-Year Yield-on-Cost % of 8.31 is 174.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on DaShenLin Pharmaceutical Group Co and its competitors. For the Healthcare Providers & Services industry, the median 5-Year Yield-on-Cost % is 3.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DaShenLin Pharmaceutical Group Co's current 5-Year Yield-on-Cost % is 8.31, which is 184% above median its own 10-year median of 2.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DaShenLin Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, DaShenLin Pharmaceutical Group Co (SHSE:603233) is currently considered Fairly Valued. The stock's GF Value™ is ¥18.30, compared to a current price of ¥18.15 — trading 0.8% below its estimated fair value. The current 5-Year Yield-on-Cost % is 8.31, which is 184% above median its 10-year median of 2.93 and 174.3% above the Healthcare Providers & Services industry median of 3.03. DaShenLin Pharmaceutical Group Co's overall GF Score™ is 93/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For DaShenLin Pharmaceutical Group Co (SHSE:603233), the current 5-Year Yield-on-Cost % is 8.31 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DaShenLin Pharmaceutical Group Co (SHSE:603233) Overvalued in 2026?
Based on GuruFocus' analysis, DaShenLin Pharmaceutical Group Co stock appears to be undervalued.
The current stock price of ¥18.15 is trading 0.8% below its estimated GF Value™ of ¥18.30.
GuruFocus considers DaShenLin Pharmaceutical Group Co to be Fairly Valued.
Key valuation signals for SHSE:603233:
5-Year Yield-on-Cost %: 8.31 (184% above median its 10-year median of 2.93)
GF Value™: ¥18.30 vs. price of ¥18.15 (0.8% below fair value)
Industry Position: 174.3% above the Healthcare Providers & Services median (#33 of 277)
No single metric tells the full story. See the SHSE:603233 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DaShenLin Pharmaceutical Group Co Ltd is engaged in the pharmaceutical manufacturing, retail, and wholesale business. The company is based on the development of the pharmacy chain. It primarily offers Chinese herbal medicine such as antibiotics and biochemical drugs. The business activities are geographically carried out through China.
93GF Score
Get the complete analysis for SHSE:603233
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603233 has been successfully added to your 
